-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
September 2016
-
Breaking News Briefs
• Everolimus (Afinitor) has been approved by the European Commission for treatment of unresectable or metastatic, well-differentiated (grade 1 or grade 2) nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin in adults with progressive disease. Everolimus is the first approved therapy in all European Union (EU) member states, plus Iceland and Norway, for…
-
FDA Corner – Interview with Reena Philip, PHD, and Eunice Lee, PHD
By Erik J. MacLaren, PhD Liquid Biopsy Testing On June 1, 2016, the U.S. Food and Drug Administration (FDA) approved the use of the cobas EGFR Mutation Test v2 to detect mutations in the epidermal growth factor receptor (EGFR) gene using patient plasma samples. IASLC Lung Cancer News spoke with Reena Philip, PhD, Director of…
-
CONVERT: An International Randomized Trial of Concurrent Chemo-Radiotherapy Comparing Twice-Daily and Once-Daily Radiotherapy Schedules in Patients with Limited-Stage Small Cell Lung Cancer and Good Performance Status
By Prof. Corinne Faivre-Finn The optimal timing and schedule of thoracic radiation in the management of limited-stage small cell lung cancer (LS-SCLC) continues to provoke debate. Since the publication of Intergroup 0096 in 1999, there had been controversy about the standard chemo-radiotherapy (cCTRT) regimen in LS-SCLC.1 Although twice-daily (BD) radiotherapy (RT) was associated with a…
-
Honoring Superb Advocacy at the 13th Annual Prevent Cancer Quantitative Imaging Workshop
By James L. Mulshine, MD On June 13, 2016, the Prevent Cancer Foundation hosted the 13th Annual Quantitative Imaging Workshop: Lung Cancer, COPD and Cardiovascular Disease – Exploring the Intersections. A major focus of the meeting related to optimization of CT imaging issues as the nation begins to implement CT screening for lung cancer. It…
-
In Memoriam – Gregory A. Curt, MD
On July 31, 2016, the lung cancer and oncology research community lost a respected researcher and leader, Gregory Curt, MD, who died at the US Walter Reed National Military Medical Center following treatment for cancer at age 64. After graduating summa cum laude from Providence College in 1974, and from the University of Rochester School…
-
Update to the “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors”
The College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) published online in April 2013 the original “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors” in Archives of Pathology & Laboratory Medicine, Journal of Thoracic Oncology,…
-
Benefit of EGFR Mutation Analysis from Plasma Cell-Free DNA for Treatment of Advanced Non-Small Cell Lung Cancer
By Tony S. K. Mok, BMSc, MD, FRCPC Patients must first be identified as having an epidermal growth factor receptor (EGFR) mutation before they can benefit from EGFR tyrosine kinase inhibitors (TKI). Furthermore, to benefit from third-generation EGFR TKI such as osimertinib, it is essential to identify the presence of resistance exon 20 T790M mutations…
-
NCI Corner – Interview with Dinah S. Singer, PHD
By Erik J. MacLaren, PhD Blue Ribbon Panel of the US National Cancer Advisory BoardDuring his State of the Union address in January 2016, President Barack Obama announced a new effort led by Vice President Joe Biden to accelerate research into cancer, known as the Vice President’s Cancer Initiative, or the National Cancer Moonshot.1 Among…
-
Genetic Differences in Lung Cancers Arising in Smokers and Never-Smokers
By Adi F. Gazdar, MD While all of the major histological forms of lung cancer are strongly associated with smoking, an important subset (about 20% worldwide, 10–15% in the US) arise in lifetime never-smokers. Lung cancer in never-smokers (LCNS) targets the female gender, East Asian ethnicity, and adenocarcinoma histology. 1 While environmental smoke exposure (ESE),…
-
Roswell Park Cancer Institute to Conduct First CimaVax Trial in the United States
By Cynthia L. Kryder, MS Roswell Park Cancer Institute in Buffalo, New York, US, expects to be the site for the first US clinical trial of CimaVax, the groundbreaking lung cancer vaccine developed at Cuba’s Center for Molecular Immunology (CIM). Set to commence within the next 6 months, pending clearance from the FDA, the trial…